Next week’s BIO International Conference promises to be an exciting global event covering important developments in healthcare, agriculture and the environment. As in years past, BPTC is pleased to be a part of this event that brings together so many of the entrepreneurs, innovators, and thought leaders in the biotechnology industry. BPTC is excited to have speakers in one of the main conference sessions and in a roundtable discussion hosted at the BioProcess International Theater in the exhibit hall.
As the cell therapy and regenerative medicine fields continue to progress, many of the products resulting from these new technologies are rapidly advancing into clinical development and in some cases into the commercial environment. At the same time, this growing important segment of the biopharmaceutical industry faces its own unique manufacturing, quality, and regulatory challenges to successfully bring more of these new products to the market. Recognizing the parallels between today’s cell therapy manufacturing hurdles and the early days of recombinant protein production, BPTC has begun to apply its skills and expertise in bioprocessing, Quality, and CMC regulatory to assist companies developing these cutting edge technologies. As part of this initiative, Dr. Susan Dana Jones, Vice President and Senior Consultant, will be leading a round table discussion on “Commercializing Cell Therapy – Challenges in GMP Manufacturing: Lessons Learned from MAbs.” This round table will be held on June 29th from 12:00-1:00 PM in the BioProcess Theater at Booth 1563 – Hall A in the BIO Process Zone.
Julia Dishman, Manager, Sales and Marketing, will also attend BIO, touching base with BPTC’s current client portfolio and meeting with companies to explain how BPTC’s broad expertise and vast experience can help companies develop and implement practical and efficient CMC strategies and fulfill their process development, manufacturing, outsourcing, and quality control requirements without adding costly headcount and infrastructure.
A few short years ago, the biopharmaceutical industry faced a serious risk of shortages in manufacturing capacity as many feared that there would be insufficient capacity to meet the growing demand for biopharmaceutical products. In response, there was a big push to expand or build new capacity coupled with concerted efforts to improve productivity and product yield at all stages of the manufacturing process. These initiatives, coupled with mergers and acquisitions, have resulted in today’s industry-wide oversupply of manufacturing capacity as well as a consolidation of capacity into the largest firms. This paradigm of supply and demand mismatches limits smaller companies’ access to capacity and will be explored in “The Biomanufacturing Capacity Conundrum: Matching Supply and Demand Over Space and Time” panel chaired by Dr. Howard L. Levine, President and Principal Consultant. The panel will be part of the Manufacturing of Biologics and Drug track, to be held on June 28th at 10:00-11:30 AM in Room 145A of the Walter E. Washington Convention Center. In addition to moderating the panel, Dr. Levine will also present “Global Trends in Biomanufacturing: Separating the Haves from the Have-nots.”
BPTC looks forward to meeting long-time friends and colleagues at BIO and hearing more about advances in technology, emerging products and companies, and current trends in the biopharmaceutical industry. And, recognizing that BIO is not all work and no play, Howard Levine and Susan Jones will be participating in the 2011 BIO 5K Run/Walk. Please contact us in advance to schedule a meeting or join us at the run/walk for a chance to meet informally and support diabetes research.
We look forward to seeing you in Washington!